Literature DB >> 24634375

SETting OP449 into the PP2A-activating drug family.

Paolo Neviani1, Danilo Perrotti.   

Abstract

The protein phosphatase 2A (PP2A) tumor suppressor is inactivated in different leukemias through the activity of its endogenous inhibitors (e.g., SET), which are aberrantly regulated by oncogenic tyrosine kinases. Like other effective and nontoxic PP2A-activating drugs (PAD), OP449 inhibits SET and impairs leukemogenesis. This further supports the immediate use of PADs in patients with leukemia. ©2014 AACR.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24634375      PMCID： PMC4286336          DOI： 10.1158/1078-0432.CCR-14-0166

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


  12 in total

1.  PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells.

Authors:  Paolo Neviani; Jason G Harb; Joshua J Oaks; Ramasamy Santhanam; Christopher J Walker; Justin J Ellis; Gregory Ferenchak; Adrienne M Dorrance; Carolyn A Paisie; Anna M Eiring; Yihui Ma; Hsiaoyin C Mao; Bin Zhang; Mark Wunderlich; Philippa C May; Chaode Sun; Sahar A Saddoughi; Jacek Bielawski; William Blum; Rebecca B Klisovic; Janelle A Solt; John C Byrd; Stefano Volinia; Jorge Cortes; Claudia S Huettner; Steffen Koschmieder; Tessa L Holyoake; Steven Devine; Michael A Caligiuri; Carlo M Croce; Ramiro Garzon; Besim Ogretmen; Ralph B Arlinghaus; Ching-Shih Chen; Robert Bittman; Peter Hokland; Denis-Claude Roy; Dragana Milojkovic; Jane Apperley; John M Goldman; Alistair Reid; James C Mulloy; Ravi Bhatia; Guido Marcucci; Danilo Perrotti
Journal:  J Clin Invest       Date:  2013-09-03       Impact factor: 14.808

2.  The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ABL-regulated SET protein.

Authors:  Paolo Neviani; Ramasamy Santhanam; Rossana Trotta; Mario Notari; Bradley W Blaser; Shujun Liu; Hsiaoyin Mao; Ji Suk Chang; Annamaria Galietta; Ashwin Uttam; Denis C Roy; Mauro Valtieri; Rebecca Bruner-Klisovic; Michael A Caligiuri; Clara D Bloomfield; Guido Marcucci; Danilo Perrotti
Journal:  Cancer Cell       Date:  2005-11       Impact factor: 31.743

3.  Apolipoprotein E and peptide mimetics modulate inflammation by binding the SET protein and activating protein phosphatase 2A.

Authors:  Dale J Christensen; Nobutaka Ohkubo; Jessica Oddo; Michael J Van Kanegan; Jessica Neil; Fengqiao Li; Carol A Colton; Michael P Vitek
Journal:  J Immunol       Date:  2011-02-15       Impact factor: 5.422

Review 4.  Chronic myeloid leukemia: mechanisms of blastic transformation.

Authors:  Danilo Perrotti; Catriona Jamieson; John Goldman; Tomasz Skorski
Journal:  J Clin Invest       Date:  2010-07-01       Impact factor: 14.808

5.  Overexpression of SET is a recurrent event associated with poor outcome and contributes to protein phosphatase 2A inhibition in acute myeloid leukemia.

Authors:  Ion Cristóbal; Laura Garcia-Orti; Cristina Cirauqui; Xabier Cortes-Lavaud; María A García-Sánchez; María J Calasanz; María D Odero
Journal:  Haematologica       Date:  2011-12-01       Impact factor: 9.941

6.  Essential requirement for PP2A inhibition by the oncogenic receptor c-KIT suggests PP2A reactivation as a strategy to treat c-KIT+ cancers.

Authors:  Kathryn G Roberts; Amanda M Smith; Fiona McDougall; Helen Carpenter; Martin Horan; Paolo Neviani; Jason A Powell; Daniel Thomas; Mark A Guthridge; Danilo Perrotti; Alistair T R Sim; Leonie K Ashman; Nicole M Verrills
Journal:  Cancer Res       Date:  2010-06-15       Impact factor: 12.701

Review 7.  Acute myeloid leukaemia.

Authors:  Elihu Estey; Hartmut Döhner
Journal:  Lancet       Date:  2006-11-25       Impact factor: 79.321

8.  FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia.

Authors:  Paolo Neviani; Ramasamy Santhanam; Joshua J Oaks; Anna M Eiring; Mario Notari; Bradley W Blaser; Shujun Liu; Rossana Trotta; Natarajan Muthusamy; Carlo Gambacorti-Passerini; Brian J Druker; Jorge Cortes; Guido Marcucci; Ching-Shih Chen; Nicole M Verrills; Denis C Roy; Michael A Caligiuri; Clara D Bloomfield; John C Byrd; Danilo Perrotti
Journal:  J Clin Invest       Date:  2007-09       Impact factor: 14.808

9.  Antagonism of SET using OP449 enhances the efficacy of tyrosine kinase inhibitors and overcomes drug resistance in myeloid leukemia.

Authors:  Anupriya Agarwal; Ryan J MacKenzie; Raffaella Pippa; Christopher A Eide; Jessica Oddo; Jeffrey W Tyner; Rosalie Sears; Michael P Vitek; María D Odero; Dale J Christensen; Brian J Druker
Journal:  Clin Cancer Res       Date:  2014-01-16       Impact factor: 12.531

10.  A potential therapeutic application of SET/I2PP2A inhibitor OP449 for canine T-cell lymphoma.

Authors:  Nobuyuki Fujiwara; Hideyoshi Kawasaki; Ryotaro Yabe; Dale J Christensen; Michael P Vitek; Takuya Mizuno; Koichi Sato; Takashi Ohama
Journal:  J Vet Med Sci       Date:  2012-11-05       Impact factor: 1.267
View more
  16 in total

1.  Macrocyclic peptides decrease c-Myc protein levels and reduce prostate cancer cell growth.

Authors:  Archana Mukhopadhyay; Laura E Hanold; Hamsa Thayele Purayil; Solomon A Gisemba; Sanjeewa N Senadheera; Jane V Aldrich
Journal:  Cancer Biol Ther       Date:  2017-07-10       Impact factor: 4.742

Review 2.  Cellular and Molecular Networks in Chronic Myeloid Leukemia: The Leukemic Stem, Progenitor and Stromal Cell Interplay.

Authors:  Danilo Perrotti; Giovannino Silvestri; Lorenzo Stramucci; Justine Yu; Rossana Trotta
Journal:  Curr Drug Targets       Date:  2017       Impact factor: 3.465

3.  The NMR-based characterization of the FTY720-SET complex reveals an alternative mechanism for the attenuation of the inhibitory SET-PP2A interaction.

Authors:  Ryan M De Palma; Stuart R Parnham; Yitong Li; Joshua J Oaks; Yuri K Peterson; Zdzislaw M Szulc; Braden M Roth; Yongna Xing; Besim Ogretmen
Journal:  FASEB J       Date:  2019-03-27       Impact factor: 5.191

4.  PPP2CA Is a Novel Therapeutic Target in Neuroblastoma Cells That Can Be Activated by the SET Inhibitor OP449.

Authors:  Celimene Galiger; Meike Dahlhaus; Michael Peter Vitek; Klaus-Michael Debatin; Christian Beltinger
Journal:  Front Oncol       Date:  2022-06-22       Impact factor: 5.738

5.  Protein phosphatase 2A activation as a therapeutic strategy for managing MYC-driven cancers.

Authors:  Caroline C Farrington; Eric Yuan; Sahar Mazhar; Sudeh Izadmehr; Lauren Hurst; Brittany L Allen-Petersen; Mahnaz Janghorban; Eric Chung; Grace Wolczanski; Matthew Galsky; Rosalie Sears; Jaya Sangodkar; Goutham Narla
Journal:  J Biol Chem       Date:  2019-12-10       Impact factor: 5.157

6.  Overexpression of PP2A inhibitor SET oncoprotein is associated with tumor progression and poor prognosis in human non-small cell lung cancer.

Authors:  Hao Liu; Yixue Gu; Hongsheng Wang; Jiang Yin; Guopei Zheng; Zhijie Zhang; Minyin Lu; Chenkun Wang; Zhimin He
Journal:  Oncotarget       Date:  2015-06-20

7.  Overlapping SETBP1 gain-of-function mutations in Schinzel-Giedion syndrome and hematologic malignancies.

Authors:  Rocio Acuna-Hidalgo; Pelagia Deriziotis; Marloes Steehouwer; Christian Gilissen; Sarah A Graham; Sipko van Dam; Julie Hoover-Fong; Aida B Telegrafi; Anne Destree; Robert Smigiel; Lindsday A Lambie; Hülya Kayserili; Umut Altunoglu; Elisabetta Lapi; Maria Luisa Uzielli; Mariana Aracena; Banu G Nur; Ercan Mihci; Lilia M A Moreira; Viviane Borges Ferreira; Dafne D G Horovitz; Katia M da Rocha; Aleksandra Jezela-Stanek; Alice S Brooks; Heiko Reutter; Julie S Cohen; Ali Fatemi; Martin Smitka; Theresa A Grebe; Nataliya Di Donato; Charu Deshpande; Anthony Vandersteen; Charles Marques Lourenço; Andreas Dufke; Eva Rossier; Gwenaelle Andre; Alessandra Baumer; Careni Spencer; Julie McGaughran; Lude Franke; Joris A Veltman; Bert B A De Vries; Albert Schinzel; Simon E Fisher; Alexander Hoischen; Bregje W van Bon
Journal:  PLoS Genet       Date:  2017-03-27       Impact factor: 5.917

8.  Deregulation of protein phosphatase 2A inhibitor SET is associated with malignant progression in breast cancer.

Authors:  Katsunori Tozuka; Pattama Wongsirisin; Shigenori E Nagai; Yasuhito Kobayashi; Miki Kanno; Kazuyuki Kubo; Ken Takai; Kenichi Inoue; Hiroshi Matsumoto; Yoshihito Shimizu; Masami Suganuma
Journal:  Sci Rep       Date:  2021-07-09       Impact factor: 4.379

9.  Cardamonin Suppresses TGF-β1-Induced Epithelial Mesenchymal Transition via Restoring Protein Phosphatase 2A Expression.

Authors:  Eun Ji Kim; Hyun Ji Kim; Mi Kyung Park; Gyeung Jin Kang; Hyun Jung Byun; Ho Lee; Chang Hoon Lee
Journal:  Biomol Ther (Seoul)       Date:  2015-03-01       Impact factor: 4.634

Review 10.  From the Biology of PP2A to the PADs for Therapy of Hematologic Malignancies.

Authors:  Maria Ciccone; George A Calin; Danilo Perrotti
Journal:  Front Oncol       Date:  2015-02-16       Impact factor: 6.244
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.